Literature DB >> 26518437

ST2 contributes to T-cell hyperactivation and fatal hemophagocytic lymphohistiocytosis in mice.

Julia E Rood1, Sheila Rao1, Michele Paessler2, Portia A Kreiger3, Niansheng Chu4, Erietta Stelekati5, E John Wherry5, Edward M Behrens1.   

Abstract

Cytokine storm syndromes, such as familial hemophagocytic lymphohistiocytosis (FHL), are lethal disorders caused by uncontrolled, systemic immune activation. In the murine model of FHL, in which perforin-deficient (Prf1(-/-)) mice are infected with lymphocytic choriomeningitis virus (LCMV), disease is driven by overabundant interferon (IFN)γ-producing LCMV-specific CD8(+) T cells thought to arise from excessive antigen stimulation through the T-cell receptor. However, this paradigm is insufficient to explain several fundamental aspects of FHL, namely, the inability of many pathogenic antigens to induce hyperinflammation, and the previously identified role of MyD88 in the disease. We now show a novel role for the MyD88-dependent interleukin-33 (IL-33) receptor, ST2, in FHL. Expression of IL-33 and ST2 is upregulated in LCMV-infected Prf1(-/-) mice. Blockade of ST2 markedly improves survival of LCMV-infected Prf1(-/-) mice and reduces the severity of multiple disease parameters, including serum levels of IFNγ. This decrease in IFNγ corresponds to a reduction in both the frequency of IFNγ(+) LCMV-specific CD8(+) and CD4(+) T cells and the magnitude of IFNγ expression in these cells. These findings demonstrate that disruption of ST2 signaling in the murine model of FHL reduces T cell-mediated production of IFNγ and suggest a revised paradigm in which danger signals such as IL-33 are crucial amplifiers of immune dysregulation in FHL. Furthermore, this study provides evidence to support blockade of ST2 as a novel therapeutic strategy for FHL.
© 2016 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26518437      PMCID: PMC4731846          DOI: 10.1182/blood-2015-07-659813

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  39 in total

Review 1.  Inherited defects in lymphocyte cytotoxic activity.

Authors:  Jana Pachlopnik Schmid; Jana P Schmid; Marjorie Côte; Mickaël M Ménager; Agathe Burgess; Nadine Nehme; Gaël Ménasché; Alain Fischer; Geneviève de Saint Basile
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

2.  The danger signal, extracellular ATP, is a sensor for an airborne allergen and triggers IL-33 release and innate Th2-type responses.

Authors:  Hideaki Kouzaki; Koji Iijima; Takao Kobayashi; Scott M O'Grady; Hirohito Kita
Journal:  J Immunol       Date:  2011-02-25       Impact factor: 5.422

Review 3.  Hemophagocytic lymphohistiocytosis (HLH): A heterogeneous spectrum of cytokine-driven immune disorders.

Authors:  Ellen Brisse; Carine H Wouters; Patrick Matthys
Journal:  Cytokine Growth Factor Rev       Date:  2014-10-28       Impact factor: 7.638

4.  Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel Il-33-LacZ gene trap reporter strain.

Authors:  Mélanie Pichery; Emilie Mirey; Pascale Mercier; Emma Lefrancais; Arnaud Dujardin; Nathalie Ortega; Jean-Philippe Girard
Journal:  J Immunol       Date:  2012-02-27       Impact factor: 5.422

5.  Antiviral memory CD8 T-cell differentiation, maintenance, and secondary expansion occur independently of MyD88.

Authors:  Adeeb H Rahman; Ruan Zhang; Christopher D Blosser; Baidong Hou; Anthony L Defranco; Jonathan S Maltzman; E John Wherry; Laurence A Turka
Journal:  Blood       Date:  2011-01-13       Impact factor: 22.113

Review 6.  Immunodeficiency secondary to anticytokine autoantibodies.

Authors:  Sarah K Browne; Steven M Holland
Journal:  Curr Opin Allergy Clin Immunol       Date:  2010-12

7.  Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function.

Authors:  O Adachi; T Kawai; K Takeda; M Matsumoto; H Tsutsui; M Sakagami; K Nakanishi; S Akira
Journal:  Immunity       Date:  1998-07       Impact factor: 31.745

8.  Perforin deficiency impairs a critical immunoregulatory loop involving murine CD8(+) T cells and dendritic cells.

Authors:  Catherine E Terrell; Michael B Jordan
Journal:  Blood       Date:  2013-05-09       Impact factor: 22.113

9.  Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis.

Authors:  Gaby Palmer; Dominique Talabot-Ayer; Céline Lamacchia; Dean Toy; Christian A Seemayer; Sébastien Viatte; Axel Finckh; Dirk E Smith; Cem Gabay
Journal:  Arthritis Rheum       Date:  2009-03

10.  Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases.

Authors:  Alexander U Lüthi; Sean P Cullen; Edel A McNeela; Patrick J Duriez; Inna S Afonina; Clare Sheridan; Gabriela Brumatti; Rebecca C Taylor; Kristof Kersse; Peter Vandenabeele; Ed C Lavelle; Seamus J Martin
Journal:  Immunity       Date:  2009-06-25       Impact factor: 31.745

View more
  18 in total

1.  CD8 T Cell Memory Increases Immunopathology in the Perforin-Deficient Model of Hemophagocytic Lymphohistiocytosis Secondary to TNF-α.

Authors:  Matthew D Taylor; Thomas N Burn; E John Wherry; Edward M Behrens
Journal:  Immunohorizons       Date:  2018-02

2.  Weathering the storm: Improving therapeutic interventions for cytokine storm syndromes by targeting disease pathogenesis.

Authors:  Lehn K Weaver; Edward M Behrens
Journal:  Curr Treatm Opt Rheumatol       Date:  2017-02-07

3.  Genetic Deficiency of Interferon-γ Reveals Interferon-γ-Independent Manifestations of Murine Hemophagocytic Lymphohistiocytosis.

Authors:  Thomas N Burn; Lehn Weaver; Julia E Rood; Niansheng Chu; Aaron Bodansky; Portia A Kreiger; Edward M Behrens
Journal:  Arthritis Rheumatol       Date:  2019-12-15       Impact factor: 10.995

Review 4.  Pediatric acute liver failure of undetermined cause: A research workshop.

Authors:  Estella M Alonso; Simon P Horslen; Edward M Behrens; Edward Doo
Journal:  Hepatology       Date:  2017-01-06       Impact factor: 17.425

5.  Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis.

Authors:  Sabrin Albeituni; Katherine C Verbist; Paige E Tedrick; Heather Tillman; Jennifer Picarsic; Rachel Bassett; Kim E Nichols
Journal:  Blood       Date:  2019-04-23       Impact factor: 22.113

6.  Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients.

Authors:  Kazusa Ishii; Marie Pouzolles; Christopher D Chien; Rebecca A Erwin-Cohen; M Eric Kohler; Haiying Qin; Haiyan Lei; Skyler Kuhn; Amanda K Ombrello; Alina Dulau-Florea; Michael A Eckhaus; Haneen Shalabi; Bonnie Yates; Daniel A Lichtenstein; Valérie S Zimmermann; Taisuke Kondo; Jack F Shern; Howard A Young; Naomi Taylor; Nirali N Shah; Terry J Fry
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

7.  Expression and potential roles of IL-33/ST2 in the immune regulation during Clonorchis sinensis infection.

Authors:  Qian Yu; Xiang-Yang Li; Xiao-Dan Cheng; Li-Ping Shen; Fan Fang; Bo Zhang; Hui Hua; Chao Yan; Ren-Xian Tang; Kui-Yang Zheng
Journal:  Parasitol Res       Date:  2016-03-05       Impact factor: 2.289

8.  Lytic viral replication and immunopathology in a cytomegalovirus-induced mouse model of secondary hemophagocytic lymphohistiocytosis.

Authors:  Ellen Brisse; Maya Imbrechts; Tania Mitera; Jessica Vandenhaute; Carine H Wouters; Robert Snoeck; Graciela Andrei; Patrick Matthys
Journal:  Virol J       Date:  2017-12-19       Impact factor: 4.099

9.  [Clinical significance of secondary hemophagocytic lymphohistiocytosis with pleural effusion].

Authors:  W Y Cheng; J Xu; L M Duan; T Tian; J J Wang; X Gao; G L Yin; J Y Huang; M M Wang; L L Liu; H X Qiu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-12-14

10.  T-cell gene therapy for perforin deficiency corrects cytotoxicity defects and prevents hemophagocytic lymphohistiocytosis manifestations.

Authors:  Sujal Ghosh; Marlene Carmo; Miguel Calero-Garcia; Ida Ricciardelli; Juan Carlos Bustamante Ogando; Michael P Blundell; Axel Schambach; Philip G Ashton-Rickardt; Claire Booth; Stephan Ehl; Kai Lehmberg; Adrian J Thrasher; H Bobby Gaspar
Journal:  J Allergy Clin Immunol       Date:  2018-01-31       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.